FindTrial
Sign In

Letybo 50 Einheiten Pulver zur Herstellung einer Injektionslösung

DRUG2 trials

Sponsors

Hamburg University, Croma-Pharma GmbH

Conditions

Moderate and severe horizontal forehead lines.Stable health without uncontrolled systemic diseases; Healthy skin testing area (forehead); Moderate to severe forehead wrinkling (in motion); Uniform sweating activity and no areas of anhidrosis (under standardized sweating conditions)

Phase 2

A prospective, randomized, evaluator- and subject blinded, multi-center investigation to assess efficacy and safety of three different dosages of the same injection pattern of LetibotulinumtoxinA in the treatment of moderate and severe horizontal forehead lines
CompletedCTIS2024-512349-17-00
Croma-Pharma GmbHModerate and severe horizontal forehead lines.
Start: 2024-11-06End: 2025-07-28Target: 90Updated: 2025-09-22

Phase 4

DIFFUSION CHARACTERISTICS OF LETIBOTULINUMTOXIN A IN COMPARISON TO ONA AND ABO-BONTA
Not yet recruitingCTIS2024-511047-26-01
Hamburg UniversityStable health without uncontrolled systemic diseases; Healthy skin testing area (forehead); Moderate to severe forehead wrinkling (in motion); Uniform sweating activity and no areas of anhidrosis (under standardized sweating conditions)
Target: 30Updated: 2024-06-07

Related Papers

Diffusion Characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its Impact on Muscle Relaxation: A Randomized Split-Face Clinical Trial
Dermatology and Therapy2025-06-176 citations